NCT04491123 (IT-ESAS) is a clinical trial in Refractory Cancer Pain, sponsored by University Hospital, Montpellier.

Who is sponsoring NCT04491123?

NCT04491123 is sponsored by University Hospital, Montpellier.

What condition does NCT04491123 study?

NCT04491123 studies Refractory Cancer Pain, Intrathecal Analgesia.

Is NCT04491123 still recruiting?

NCT04491123 is currently completed. Last updated 29 July 2020.

Last reviewed 2020-07-29 · How we verify

NCT04491123: IT-ESAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intrathecal Analgesia Effects on Cancer Patients Discomfort Symptoms

Completed Last updated 29 July 2020

What this trial tests

trial in Refractory Cancer Pain in 20 participants. Completed in 30 June 2020.

Timeline

1 November 2018

Primary endpoint
30 April 2020

30 June 2020

Quick facts

Lead sponsor	University Hospital, Montpellier
Status	Completed
Study type	OBSERVATIONAL
Enrollment	20
Start date	1 November 2018
Primary completion	30 April 2020
Estimated completion	30 June 2020
Sites	1 location across France

Conditions studied

Refractory Cancer Pain — all drugs for Refractory Cancer Pain →
Intrathecal Analgesia — all drugs for Intrathecal Analgesia →

Sponsor

University Hospital, Montpellier

Who can join

18 and older, any sex, with Refractory Cancer Pain or Intrathecal Analgesia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Intrathecal analgesia is used in refractory cancer pain because of drug sides effects or intractable pain. The aim of this approach is to improve pain management, and also to improve patient comfort. This study will assess patient discomfort symptoms before and after setting up intrathecal analgesia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University Hospital, Montpellier trials

Trials by the same sponsor.

NCT07524127 — Phenotyping of Type 2 Inflammation Profile by Rheology of Nasal Secretions and Tissue Quantification of Eosinophilic Pol · NA · not yet recruiting
NCT07255495 — Effects of Neuromuscular Scoliosis Surgery on Nutritional Metabolism · NA · not yet recruiting
NCT07534189 — Prospective Cohort Study Evaluating a Thermal Spa Programme in Symptomatic Knee Osteoarthritis · NA · not yet recruiting
NCT07515638 — Immun4Cure Cohort of Autoimmune Diseases · not yet recruiting
NCT07406516 — Identification of Kinematic Variables Specific of Patellar Tendinopathy in Athletes at Risk · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04491123 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Montpellier
Last refreshed: 29 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04491123.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing